In 2023, the trade exchange (includes international purchases and sales) of Heterocyclic Compounds Containing in the Structure Cycle Thiazole, Incl. Hydrogenated Unfused was US$79.9M.
In 2023, the states with the most international sales in Heterocyclic Compounds Containing in the Structure Cycle Thiazole, Incl. Hydrogenated Unfused were Estado de México (US$26.6k).
The states with the most international purchases in 2023 were Ciudad de México (US$13.4M), Nuevo León (US$12.4M), Jalisco (US$1.47M), Morelos (US$807k), and Estado de México (US$770k).
In 2023, the main commercial destinations of Heterocyclic Compounds Containing in the Structure Cycle Thiazole, Incl. Hydrogenated Unfused were Colombia (US$20k), United States (US$5.11k), Chile (US$1.02k), Peru (US$510), and Brazil (US$2).
The main commercial origins of Heterocyclic Compounds Containing in the Structure Cycle Thiazole, Incl. Hydrogenated Unfused in 2023 were Switzerland (US$12.1M), India (US$6.98M), Spain (US$4.85M), China (US$3.12M), and Netherlands (US$844k).
In the global context, the main exporting countries of Heterocyclic Compounds Containing in the Structure Cycle Thiazole, Incl. Hydrogenated Unfused in 2022 were Switzerland (US$1.59B), Ireland (US$902M), and China (US$623M). In the same year, the main importing countries of Heterocyclic Compounds Containing in the Structure Cycle Thiazole, Incl. Hydrogenated Unfused were United States (US$1.34B), Canada (US$1.22B), and Brazil (US$385M).